The Iliac/SFA/Popliteal Center

Filter Your Results




Drug-Eluting Balloons in the SFA

March 2010—Dierk Scheinert, MD, discusses the THUNDER and FemPac trial results and previews new studies that will evaluate drug-coated balloons versus plain old balloon angioplasty.

COMPLETE SE and Other SFA Trials

Khung Keong Yeo, MD, and John R. Laird Jr, MD

March 2010—A look at the ongoing trials of self-expanding stents in the superficial femoral artery.

Evaluating the Zilver PTX Stent

Michael D. Dake, MD; Gary M. Ansel, MD, FACC; and Anthony O. Ragheb, PHD

March 2010—Principal investigators discuss the clinical study design and initial results with the Zilver PTX drug-eluting peripheral stent in the SFA.


Krishna Rocha-Singh, MD, FACC, FSCAI, FSVM

March 2010—A new standard in femoropopliteal artery nitinol stent trial design.

The COBRA Trial

Sivavasavi Dinakaran, MD; Praveen Mehta, MD; Daniel Tran, MSC; Emmanouil S. Brilakis, MD; Subhash Banerjee, MD; and Tony S. Das, MD

March 2010—How will cryotherapy compare to conventional balloon angioplasty in peripheral vascular interventions?

The STROLL Study

Andrew J. Feiring, MD, FACC, FSCAI

March 2010—Nitinol self-expandable stent placement for the treatment of obstructive SFA disease.


Gary M. Ansel, MD, FACC; Patrick J. Geraghty, MD, FACS; Mark Mewissen, MD; and Michael R. Jaff, DO

March 2010—Comparing bare-nitinol stents to stent grafts in long superficial femoral artery lesions in this unique trial.

The VIPER Trial

Richard R. Saxon, MD, FSIR

March 2010—With heparin bonded to the surface and a contoured edge, how will stent grafts perform in SFA revascularization?




Contact Info

For advertising rates and opportunities, contact:
Craig McChesney

Stephen Hoerst

Charles Philip

About Endovascular Today

Endovascular Today is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in the endovascular field. Our Editorial Advisory Board is composed of the top endovascular specialists, including interventional cardiologists, interventional radiologists, vascular surgeons, neurologists, and vascular medicine practitioners, and our publication is read by an audience of more than 22,000 members of the endovascular community.